Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and upgrading its ...
The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...
1don MSN
The GLP-1 drug giant’s shares have surged this year. Eli Lilly could keep climbing thanks to strong demand for Mounjaro and ...
The rivalry between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) has heated up as both companies vie for ...
Siding With Novo and Lilly, Court Agrees to First Tackle ‘Cross Cutting Issues” in GLP-1 Litigations
In agreeing with Novo Nordisk and Eli Lilly, Pennsylvania judge Karen Spencer Marston said the court should first settle ...
Novo Nordisk 's ( NVO 1.19%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is ...
Eli Lilly this week announced plans to sell single-dose vials of its weight loss drug Zepbound directly to consumers. Novo ...
President Biden and I co-authored an op-ed demanding that Novo Nordisk and Eli Lilly substantially lower the outrageously ...
Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more.
Eli Lilly is offering 2.5-milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month, ...
Novo Nordisk and Eli Lilly, the dominant players in the GLP-1R market, are expected to collectively capture 94 per cent of ...
Eli Lilly is cutting the cost of certain weight loss drugs, with new single-dose vials costing less than other medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results